Word

THIOLOGICS

Status

Dead

Status Code

709

Status Date

Friday, February 26, 2021

Serial Number

79115013

Registration Number

4452854

Registration Date

Tuesday, December 24, 2013

Mark Type

4000

Filing Date

Friday, January 27, 2012

Published for Opposition

Tuesday, October 8, 2013

Cancellation Date

Friday, February 26, 2021

Trademark Owner History

UCL Business plc - Original Registrant

Classifications

1 Chemicals for use in bioconjugation, reversible bioconjugation, irreversible bioconjugation, reversible cysteine protection, surface modification, and prodrug production; biochemicals, namely, polypeptides, polypeptides for in vivo applications, polypeptides for in vitro applications, polynucleic acids, polynucleic acids for in vivo applications, and polynucleic acids for in vitro applications; biomolecules, namely, proteins, peptides, antibodies, antibody fragments, antibody mimetic proteins, and polynucleic acids; chemical products for diagnostic use, namely, conjugates of polypeptides with small molecule drugs, imaging agents, and radionuclides for medical applications; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in medical research; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in diagnosis and treatment of disease

5 Pharmaceutical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; biological preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic preparations for medical purposes; diagnostic preparations for scientific or research use; diagnostic kits consisting primarily of antibody preparations, namely, antibody bioconjugates, namely, antibody-drug conjugates, antibody-radionuclide conjugates and antibody-imaging agent conjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of chemical products for medical diagnostic use, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of biochemical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans

42 Scientific and technological services, namely, design and assembly of polypeptide bioconjugates and polynucleic acid bioconjugates, and design and optimization of proprietary bioconjugation technologies; biological research; chemical research and analysis; scientific advisory services relating to research and development in the field of diagnostic preparations and diagnostic products; providing scientific information and advisory services in the fields of scientific research and design, and biological and chemical research

THIO LOGICS

Trademark Events

Jan 29, 2022

Total Invalidation Processed By The Ib

Dec 23, 2021

Total Invalidation Of Reg Ext Protection Sent To Ib

Dec 23, 2021

Invalidation Processed

Oct 26, 2021

Total Invalidation Of Reg Ext Protection Created

Oct 2, 2021

New Representative At Ib Received

Feb 26, 2021

Cancelled Section 71

Dec 24, 2018

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Jun 6, 2014

Final Decision Transaction Processed By Ib

May 19, 2014

Final Disposition Notice Sent To Ib

May 19, 2014

Final Disposition Processed

Mar 24, 2014

Final Disposition Notice Created, To Be Sent To Ib

Dec 24, 2013

Registered-Principal Register

Oct 8, 2013

Official Gazette Publication Confirmation E-Mailed

Oct 8, 2013

Published For Opposition

Oct 7, 2013

Notification Processed By Ib

Sep 18, 2013

Notification Of Possible Opposition Sent To Ib

Sep 18, 2013

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Sep 18, 2013

Notification Of Notice Of Publication E-Mailed

Aug 30, 2013

Law Office Publication Review Completed

Aug 22, 2013

Approved For Pub - Principal Register

Aug 20, 2013

Teas/Email Correspondence Entered

Aug 20, 2013

Correspondence Received In Law Office

Aug 20, 2013

Teas Request For Reconsideration Received

Mar 7, 2013

Notification Of Final Refusal Emailed

Mar 7, 2013

Final Refusal E-Mailed

Mar 7, 2013

Final Refusal Written

Feb 14, 2013

Teas/Email Correspondence Entered

Feb 14, 2013

Correspondence Received In Law Office

Feb 7, 2013

Assigned To Lie

Feb 6, 2013

Teas Response To Office Action Received

Aug 30, 2012

Refusal Processed By Ib

Aug 7, 2012

Non-Final Action Mailed - Refusal Sent To Ib

Aug 7, 2012

Refusal Processed By Mpu

Aug 7, 2012

Non-Final Action (Ib Refusal) Prepared For Review

Aug 7, 2012

Application Filing Receipt Mailed

Aug 6, 2012

Non-Final Action Written

Aug 3, 2012

Assigned To Examiner

Aug 3, 2012

New Application Office Supplied Data Entered In Tram

Aug 2, 2012

Sn Assigned For Sect 66a Appl From Ib